BlueCrest Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

BlueCrest Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-10,714	Closed	-$330K	–	1886
2018 Q1	$330K	Buy	+10,714	New	+$345K	0.01%	992

Other funds holding RVNC

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

NCM

NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlueCrest Capital Management's RVNC Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2018, closing a stake of 10,714 shares — an estimated $330K sold.

BlueCrest Capital Management first reported a position in RVNC in Q1 2018 and held it in 1 quarter. The position peaked at $330K in Q1 2018. 110 funds tracked by Wall St. Rank hold RVNC as of Q2 2018.

BlueCrest Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
BlueCrest Capital Management sold 10,714 Revance Therapeutics, Inc. shares in Q2 2018, an estimated $330K.
BlueCrest Capital Management first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 1 quarter.
BlueCrest Capital Management's Revance Therapeutics, Inc. position peaked at $330K in Q1 2018.
110 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.